Hemogenyx Pharmaceuticals Plc
HOPHF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$15.02M
Close$
$-0.13
105.4% downside
Current Fair Value
105.4% downsideOvervalued by 105.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $15.02 Million |
|---|---|
| Enterprise Value | $12.30 Million |
| Earnings per Share | $-2.2 |
| Beta | 1.53 |
| Outstanding Shares | 6,444,216 |
Return
| Return on Equity | -511.30% |
|---|---|
| Return on Assets | -321.97% |
| Return on Invested Capital | -305.77% |
Valuation & Multiples
| P/E Ratio | -3.85 |
|---|---|
| PEG | -12.19 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.72 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.15 |
| Debt to Equity | 0.43 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Hemogenyx Pharmaceuticals Plc
16 employees
CEO: Vladislav Sandler
Hemogenyx Pharmaceuticals Plc is a preclinical biotechnology company dedicated to the discovery, advancement, and commercialization of innovative therapies for various blood diseases. The firm's pipeline is heavily focused on creating no...